Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Kallirroi I Kalantzi"'
Autor:
Apostolos Kotidis, Panagiotis Andronikos, Stylianos Chantanis, Maria Riga, Athanasios Kartalis, Filippos Anastasiadis, Gerasimos Markatos, Demosthenes B. Panagiotakos, Charalampos Petras, Ioannis Myroforou, Grammatiki E Tsikouri, Panagiotis Vavoulis, Pavlos Pavlidis, Maria E. Tsoumani, Dionysios Hatzopoulos, Eleni Grigoriadou-Skouta, Alexandros D. Tselepis, Stefanos Fousas, Theano Aslanidou, Konstantinos Zisimos, Matina Kouvari, Anastasios Georgiopoulos, Nikolaos G Patsourakos, Kalliopi Gerakiou, Emmanuel I Tsikouris, Anestis Orkopoulos, Constantinos Vogiatzidis, Anastasios Lyras, Petros Efraimidis, Konstantinos Thomaidis, Maria-Gabriella Vitali, Aristeidis Mikrogeorgiou, Panagiotis Grigoropoulos, Marina Skouloudi, Nikolaos Smyrnioudis, George Vitsas, Kallirroi I Kalantzi
Publikováno v:
Archives of Medical Science : AMS
Introduction The use of generic drugs is continuously growing; however, there are limited epidemiological data regarding the therapeutic equivalence of each original drug formulation with its generic counterparts. We evaluated the 12-month composite
Autor:
Leonidas Peltekis, Ioannis Efthimiadis, Nikolaos Prokopakis, Zaharias Christogiannis, Maria Voukelatou, Maria Thoma, Ioannis Sinteles, Adamantios Bourdakis, Alexandros D. Tselepis, Maria E. Tsoumani, Haralampos J. Milionis, Ioannis Giatrakos, Giorgos Hatziathanasiou, Spiros Konstantinou, Nikolaos Kipouridis, Kyriafina Terzoudi, Demosthenes B. Panagiotakos, Konstantinos Vemmos, Evangelos Kazakos, Christos Charmpas, Dimitrios Nikolopoulos, Ioannis Vakalis, Ioannis Ntalas, John A. Goudevenos, Antonios Draganigos, Vassilios Giogiakas, Ioannis Xaraktsis, Giorgos Giannakoulas, Christos S. Stroumbis, Giorgos Goumas, Konstantinos Vardakis, Vasileios Vasilakopoulos, Nikolaos Dimoulis, Karmelos Tsilias, Kallirroi I Kalantzi
Publikováno v:
Journal of Cardiovascular Pharmacology and Therapeutics. 21:516-525
Background: In the present clinical trial, we compared the efficacy and safety of the generic clopidogrel besylate (CB) with the innovator clopidogrel hydrogen sulfate (CHS) salt in patients eligible to receive clopidogrel. Methods: A prospective 2-a
Autor:
Maria Thoma, Alexandros D. Tselepis, Konstantinos Mavronasos, Dimitrios Logothetis, Konstantina Martiadou, Petros Darmanis, Konstantinos Ipeirotis, Stefanos Gkiokas, Christos Asimakopoulos, Demosthenes B. Panagiotakos, Maria E. Tsoumani, Stergios Zisekas, Miltiadis Papaioakeim, Dimitrios Adamopoulos, Ioannis Klonaris, Alexandros Zenetos, Dimitrios V. Stergiou, Georgios Papadimitriou, Kyriaki Kitikidou, Vasileios G. Chantzichristos, Alexandra Dimitriadou, Theodoros Mais, Emmanouil Stefanakis, Kallirroi I Kalantzi, Ioannis Ntalas, Kosmas Sofillas, Athanasios Maragiannis, Konstantinos Mainas, Dimitrios Mitropoulos, Achilleas Papadopoulos, Aglaia Kostaki, John A. Goudevenos, Adamantios Bourdakis, Sotiria Stabola, Ioannis Michelongonas
Publikováno v:
Current vascular pharmacology. 17(6)
Background: Triflusal has demonstrated an efficacy similar to aspirin in the prevention of vascular events in patients with acute myocardial infarction (ΜΙ) and ischaemic stroke but with less bleeding events. Objective: We performed a randomised, m
Autor:
Ioannis Ntalas, John A. Goudevenos, Kallirroi I Kalantzi, Haralampos J. Milionis, Anastazia Kei
Publikováno v:
Angiology. 65:473-490
Ischemic heart disease and cerebrovascular disease remain major health problems with associated mortality and quality-of-life consequences. Antiplatelet agents, including thienopyridines and the new P2Y12 inhibitors, have been shown to improve surviv
Publikováno v:
Current Vascular Pharmacology. 12:766-777
Clopidogrel is a thienopyridine that selectively and irreversibly inhibits the ADP purinergic receptor P2Y 12 and the subsequent ADP-mediated platelet activation. Clopidogrel has been approved for clinical use as clopidogrel hydrogen sulfate (bisulfa
Publikováno v:
Current Vascular Pharmacology. 10:539-549
Inflammation of the vascular wall is considered as the principal underlying mechanism in the development of atherosclerosis. Besides their specific functions in haemostasis via thrombus formation after an endothelial injury, a growing body of evidenc
Publikováno v:
Expert Review of Clinical Pharmacology. 5:319-336
Platelets play an important role in atherothrombotic disease. The currently available antiplatelet drugs target key steps of platelet activation including thromboxane A(2) synthesis, ADP-mediated signaling, and glycoprotein IIb/IIIa-mediated platelet
Autor:
Kallirroi I Kalantzi, Ioannis Goudevenos, Andromachi A Dimitriou, Alexandros D. Tselepis, Ioannis Ntalas, Maria E. Tsoumani
Publikováno v:
Expert Opinion on Pharmacotherapy. 13:149-158
The efficacy of clopidogrel therapy in patients with an acute coronary syndrome (ACS) has been established using the clopidogrel hydrogen sulfate (CHS) formulation. In this study we compared the antiplatelet effectiveness of a generic clopidogrel sal
Autor:
Ioannis Goudevenos, Maria E. Tsoumani, Kallirroi I Kalantzi, Andromachi A Dimitriou, Alexandros D. Tselepis, Ioannis Ntalas
Publikováno v:
Angiology. 63:547-551
The efficacy of clopidogrel therapy in patients with an acute coronary syndrome (ACS) has been established using the clopidogrel hydrogen sulfate (CHS) formulation. We compared the antiplatelet effectiveness of long-term administration of the origina
Autor:
Alexandros D. Tselepis, Ioannis Goudevenos, Andromaxi A. Dimitriou, Constantinos C. Tellis, Kallirroi I Kalantzi, Maria E. Tsoumani
Publikováno v:
Journal of Thrombosis and Haemostasis. 9:2371-2378
Summary. Background: The paraoxonase activity of the enzyme paraoxonase-1 (PON-1) associated with high-density lipoprotein (HDL) may significantly influence clopidogrel’s antiplatelet and clinical efficacy as a result of its involvement in the clop